Short Interest in Redhill Biopharma Ltd. (NASDAQ:RDHL) Decreases By 50.9%

Redhill Biopharma Ltd. (NASDAQ:RDHL) was the recipient of a significant drop in short interest in August. As of August 14th, there was short interest totaling 14,705 shares, a drop of 50.9% from the July 30th total of 29,926 shares. Currently, 0.3% of the shares of the stock are sold short. Based on an average daily trading volume, of 28,818 shares, the short-interest ratio is currently 0.5 days.

Institutional Trading of Redhill Biopharma

A hedge fund recently bought a new position in Redhill Biopharma stock. Yorkville Advisors Global LP purchased a new position in shares of Redhill Biopharma Ltd. (NASDAQ:RDHL) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 386,593 shares of the biotechnology company’s stock, valued at approximately $398,000. Redhill Biopharma comprises about 0.3% of Yorkville Advisors Global LP’s holdings, making the stock its 19th largest holding. Yorkville Advisors Global LP owned approximately 7.57% of Redhill Biopharma as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 7.20% of the company’s stock.

Redhill Biopharma Trading Up 58.1%

NASDAQ:RDHL traded up $0.38 during trading hours on Monday, hitting $1.04. The company had a trading volume of 91,906,473 shares, compared to its average volume of 812,996. Redhill Biopharma has a 1 year low of $0.57 and a 1 year high of $2.79. The company has a market cap of $6.35 million, a P/E ratio of 0.00 and a beta of 5.00. The company has a 50-day moving average of $0.70 and a 200 day moving average of $0.84.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Redhill Biopharma in a research note on Monday, August 3rd. One research analyst has rated the stock with a Sell rating, According to MarketBeat, Redhill Biopharma presently has a consensus rating of “Sell”.

About Redhill Biopharma

RedHill Biopharma Ltd. is a specialty biopharmaceutical company focused on the development and commercialization of proprietary, orally-administered small molecules for the treatment of inflammatory, gastrointestinal and oncology indications. Founded in 2009 and headquartered in Tel Aviv, Israel, RedHill is publicly traded on the Nasdaq under the symbol RDHL. The company’s strategy centers on in-licensing late-stage clinical candidates and advancing them through regulatory review toward global commercialization.

RedHill’s lead marketed product, Talicia® (formerly RHB-105), is an FDA-approved, three-drug treatment for Helicobacter pylori infection, co-commercialized in the United States through a partnership with Bausch Health.